3 Drugs That Are Moving the Needle at Johnson & Johnson

3 Drugs That Are Moving the Needle at Johnson & Johnson

Source: 
Motley Fool
snippet: 

J&J's fastest growing drugs did a lot of heavy-lifting last quarter, and as a result drug revenue was able to increase despite biosimilar competition to its best-selling drug Remicade. Remicade is a widely used autoimmune disease drug, and until recently it accounted for more than 15% of J&J's pharmaceutical revenue.